ResearchMoz added Latest Research Report titled ” Gastroesophageal (GE) Junction Carcinoma Treatments Market – Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 – 2019 ” to it’s Large Report database.
Gastroesophageal (GE)junction carcinoma is a type of cancer thatdevelops between the esophagus and the tube that connects the stomach with the mouth. This type of cancer begins when carcinogens such as, alkylating agents or chemical particles enter in the esophagus or stomach. Alcohol consumption and tobacco smoking some of the major causes associated with gastroesophageal junction carcinoma.Prime symptoms of gastroesophageal junction carcinoma include weight loss, chest pain, fatigue, indigestion and dysphagia (difficulty to swallow food but comfortable with liquid). The symptoms of this condition are discovered on one to six month after the beginning of cancer. People with 60 to 70 years of ageand above are more prone to get this form of carcinoma.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=194552
Treatmentsfor gastroesophageal junction carcinoma depends on the patient’s health condition and the stages of carcinoma. Following are the common treatment option for this cancer:
Combination therapy(radiation and chemotherapy)
Laser or photodynamic therapy
The global cancer treatment market is witnessing a rapid growth in Gastroesophageal Junction Carcinoma with the increase in the geriatric population worldwide and their high susceptibility to GE junction cancer. In June 2012, the American Geriatrics Society reported that about 30% of the American population were aged sixty five and above.High treatment cost associated with GE junction cancer is reported to be a major factor which will hinder the growth of this market.
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Geographically, North America leads the global GE junction carcinoma market and is followed by Europe with the increase in awareness among the general population and technological developments in available treatments. However, high prevalence rate accounts Asia-Pacific (especially China) as an emerging growing market for GE junction carcinoma.
Some of the market players in this industry include, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, MedImmune, LLC, Millennium Pharmaceuticals, Inc., Amgen, Inc., Bristol-Myers Squibb Company and Merrimack Pharmaceuticals, Inc.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
Rest of the World
This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Albany NY, United States – 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/